Patients who used Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs and were diagnosed with gastroparesis through a gastric emptying study, or with the eye condition NAION, may qualify to file a lawsuit. Learn who qualifies, which drugs are included, and where the federal GLP-1 litigation stands today.
A study published in the British Journal of Ophthalmology found that Wegovy users may face nearly five times the risk of developing ischemic optic neuropathy (ION), including non-arteritic anterior ischemic optic neuropathy, or NAION, compared to patients taking Ozempic.
(more…)Lawsuits involving Ozempic (semaglutide) and other GLP-1 receptor agonists have been increasing as more patients report sudden vision loss and diagnoses of non-arteritic anterior ischemic optic neuropathy, or NAION. This condition affects the optic nerve and can result in permanent vision damage.
(more…)Ozempic (semaglutide) and other GLP-1 receptor agonists have become widely used medications for type 2 diabetes and weight loss. While many patients take these drugs without experiencing serious side effects, growing research and an increasing number of lawsuits have raised concerns about a potential link to a serious eye condition known as non-arteritic anterior ischemic optic neuropathy, or NAION.
(more…)People who developed sudden vision loss or were diagnosed with non-arteritic anterior ischemic optic neuropathy, often called NAION, after using Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs may have legal options. Patients across the United States have begun filing lawsuits alleging that these medications caused serious optic nerve injuries that can lead to permanent vision impairment or blindness.
(more…)Millions of Americans take Ozempic or other glucagon-like peptide-1 (GLP-1) agonist drugs such as Wegovy, Rybelsus, or Mounjaro to manage type-2 diabetes and for weight loss.
(more…)New research and growing legal investigations are raising serious concerns about whether certain GLP-1 medications such as Ozempic, Wegovy, and Mounjaro may increase the risk of a rare but potentially devastating eye condition called Non-Arteritic Anterior Ischemic Optic Neuropathy, commonly known as NAION.
(more…)The manufacturers of Ozempic, Mounjaro, and other diabetes and weight loss drugs known as GLP-1 agonists are facing at least 21 lawsuits filed in federal court by patients who developed an eye condition known as NAION after taking these drugs.
(more…)Patients who used Ozempic or Wegovy (semaglutide) to treat type 2 diabetes may be up to eight times more likely to develop vision loss or blindness from an eye condition known as NAION, according to the results of a recent study.
(more…)According to a new study, nearly 70% of all hospital emergency room visits involving side effects from weight loss and diabetes drugs such as Ozempic (semaglutide) were caused by stomach problems, including gastroparesis.
(more…)
